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Abstract 29 
Urban particulate matter (UPM) air pollution and vitamin D deficiency are detrimentally 30 
associated with respiratory health; this is hypothesised to be due in part to regulation of IL-31 
17A, which UPM is reported to promote. Here we use a myeloid (m)DC-memory CD4+ T cell 32 
co-culture system to characterize UPM-driven IL-17A+ cells, investigate the mechanism by 33 
which UPM-primed DCs promote this phenotype and address evidence for cross-regulation 34 
by vitamin D. CD1c+ mDCs were cultured overnight with or without a reference source of 35 
UPM and/or active vitamin D (1,25(OH)2D3) before co-culturing with autologous memory 36 
CD4+ T cells. Supernatants were harvested for cytokine analysis on day 5 of co-culture and 37 
intracellular cytokine staining performed on day 7. UPM-primed DCs increased the 38 
proportion of memory CD4+ T cells expressing Th17-associated cytokines IL-17A, IL-17F 39 
and IL-22 as well as IFN, GM-CSF and granzyme B. Notably, a large proportion of the 40 
UPM-driven IL-17A+ cells co-expressed these cytokines, but not IL-10, indicative of a pro-41 
inflammatory Th17 profile. UPM-treated DCs expressed elevated levels of il23 mRNA and 42 
increased secretion of IL-23p40. Neutralisation of IL-23 in culture reduced the frequency of 43 
IL-17A+IFN+ cells without affecting cell proliferation. 1,25(OH)2D3 counteracted the UPM-44 
driven DC maturation and inhibited the frequency of IL-17A+IFN+ cells, most prominently 45 
when DCs were co-treated with the corticosteroid dexamethasone, whilst maintaining anti-46 
inflammatory IL-10 synthesis. These data indicate that UPM might promote an inflammatory 47 
milieu in part by driving an IL-23-driven pro-inflammatory Th17 response. Restoring vitamin 48 
D sufficiency may counteract these UPM-driven effects without obliterating important 49 
homeostatic immune functions. 50 
 51 
Key Words: Air pollution, vitamin D, Th17, IL-23, corticosteroids.  52 
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Introduction 53 
Asthma is a complex and heterogeneous disease that is estimated to affect over 300 million 54 
people worldwide. It is typically well-controlled with β2-receptor agonists and corticosteroids. 55 
However 5-10% of asthmatics have particularly poorly controlled severe disease that is 56 
frequently associated with a neutrophilic infiltrate alongside elevated levels of IL-17A, the 57 
prototypical cytokine of Th17 cells, throughout the airways (1). Chronic obstructive 58 
pulmonary disease (COPD), another respiratory disease that is predicted to be the third 59 
leading cause of mortality by 2020, is also characterised by elevated levels of IL-17A in the 60 
bronchial submucosa and peripheral blood (2). Homeostatically Th17 cells are nevertheless 61 
essential for protecting against bacteria and fungi such as Klebsiella pneumoniae and 62 
Candida albicans at mucosal surfaces.  63 
 64 
Th17 cells are not a homogenous population, and a subset of pro-inflammatory ‘Th17.1’ cells 65 
has been described that drives experimental autoimmune encephalomyelitis in mice (3, 4). 66 
Upon T cell receptor stimulation, Th17.1 cells differentiate in the presence of IL-23 to co-67 
express the Th17-associated cytokines IL-17A, IL-17F and IL-22 with Th1-associated IFNγ, 68 
but not the anti-inflammatory mediator IL-10. Zielinski et al. showed that human Candida 69 
albicans-specific Th17 cells produced both IL-17A and IFNγ, but not IL-10 upon re-70 
stimulation (5). Beyond Th1 and Th17 cytokines, the pathogenicity of IL-23-driven Th17 cells 71 
appears to be dependent upon GM-CSF, such that in the absence of GM-CSF autoimmune 72 
neuroinflammation does not develop in mice (6, 7). Ramesh et al. further phenotyped human 73 
pro-inflammatory Th17.1 cells by culturing CD4+ T cells in the presence of anti-CD3, anti-74 
CD28 and IL-23 (8); these cells were identified as CCR6+CXCR3hiCCR4loCCR10-CD161+, 75 
transiently expressing c-Kit and stably expressing multi-drug resistance type 1 (MDR1). This 76 
is of interest because levels of both IL-17A and IFN are heightened in severe and steroid 77 
refractory asthma (9-11), and MDR1+ pro-inflammatory Th17 cells were found to be 78 
refractory to a range of corticosteroids (8).  79 
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 80 
The increase in the prevalence of chronic respiratory diseases over recent decades 81 
highlights a key role for environmental factors in disease development and progression (12). 82 
In particular, there is a substantial body of epidemiological data that detrimentally link both 83 
poor air quality and vitamin D deficiency to asthma and COPD (13, 14). Exposure to 84 
elevated concentrations of ambient particulate matter (PM) has been associated with asthma 85 
exacerbations as well as increased hospitalisation and medication usage, with emerging 86 
evidence supporting a role in the initiation of asthma (15). Importantly within the 87 
epidemiological literature air pollution-triggered asthma exacerbations occur with a 2-5 day 88 
lag, suggesting that the role of the pollution itself may be indirect, possibly via perturbation of 89 
lymphocyte responses, rather than by the direct induction of bronchoconstriction or 90 
immediate triggering of innate immune responses (16). Consistent with this view, a reduction 91 
in PM-induced airway hyperresponsiveness and mucus cell hyperplasia has been reported 92 
in Rag1-/- mice that lack lymphocytes (17).  93 
 94 
Vitamin D deficiency has also been associated with the increased incidence and severity of 95 
many respiratory diseases, including asthma, an observation that has been reviewed in 96 
detail elsewhere (14, 18). The majority of vitamin D is generated when ultraviolet-B radiation 97 
photolyses 7-dehydrocholesterol in the skin into vitamin D3. Vitamin D3 can then be 98 
converted into the active form of vitamin D, namely 1,25(OH)2D3, by the enzyme CYP27B1 99 
which is present in the kidneys and various peripheral immune cells. Whilst statistically 100 
significant associations have been reported between respiratory diseases and both air 101 
pollution and vitamin D deficiency (discussed above), the underlying molecular mechanisms 102 
by which these environmental factors influence pathophysiology are not fully understood. 103 
Furthermore, although it has been proposed that vitamin D may counteract the detrimental 104 
effects of UPM, how it achieves this remains to be fully elucidated. 105 
 106 
 5 
In vivo, the inhaled PM and desorbed components are presented to the immune system in 107 
part by interdigitating myeloid dendritic cells (mDCs) that line the airways and lung 108 
parenchyma. DCs can then traffic to the mesenteric lymph node and modulate effector T cell 109 
function, or can act more locally to promote airway inflammation (19). Whereas UPM has 110 
been reported to promote the maturation of DCs (19), vitamin D has independently been 111 
shown to have the opposite effect, acting to promote a tolerogenic DC phenotype (20). 112 
Within the lung, memory CD4+ T cells are extremely abundant and therefore any modulation 113 
of them by UPM-primed DCS may play an important role in air pollution-induced disease 114 
exacerbations (21), something which the current study sought to address. 115 
 116 
This study aimed to phenotype the cytokine profile of human memory CD4+IL-17A+ T cells 117 
generated following co-culture with UPM pre-treated CD1c+ mDCs, and specifically to 118 
identify whether UPM promoted a specifically pro-inflammatory Th17 phenotype, as well as 119 
the DC-derived signals that might drive such a response. Vitamin D has independently and 120 
repeatedly been shown to down-regulate Th17 responses both in vitro and in vivo (14). We 121 
therefore further addressed whether 1,25(OH)2D3 could counteract any effects of UPM in 122 
promoting a potentially pathogenic Th17 response.   123 
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Materials and Methods 124 
Cell isolation  125 
PBMCs were isolated from healthy donors by means of density centrifugation (Axis-Shield) 126 
(REC 14/LO/1699) and CD1c+ DCs positively selected (Miltenyi Biotec; >98% CD11c+HLA-127 
DR+). Unlabelled PBMCs were frozen overnight in RPMI-1640 containing 40% FCS and 128 
10% DMSO then CD4+CD45RO+ cells isolated by negative selection (Miltenyi Biotec; 129 
>98.5% CD4+CD45RO+). Cells were re-suspended in RPMI-1640 supplemented with 10% 130 
human AB serum, 2mM L-glutamine and 50mg/ml gentamycin. Inferior turbinate tissue was 131 
donated by patients undergoing turbinate resection (REC 12/LO/1931) and CD1a+ DCs 132 
positively isolated as previously described (22) (>95% CD11c+HLA-DR+ excluding debris).  133 
 134 
Cell culture 135 
1x104/ml DCs were cultured in a U-bottomed 96-well plate for 20 hours with 50ng/ml rhGM-136 
CSF +/- 5μg/ml NIST (3% methanol vehicle control (VC)), 100nM 1,25(OH)2D3 (BIOMOL 137 
Research Labs; 0.01% DMSO VC), 100nM dexamethasone (Sigma Aldrich) and/or 2μg/ml 138 
anti-IL-23p19 or the relevant isotype control (R&D Systems) unless stated. DC supernatants 139 
were harvested after 20 hours and 2x105 autologous memory CD4+ T cells added. Five days 140 
later supernatants were harvested and cells transferred to a 48-well plate with 10IU/ml rhIL-2 141 
(Eurocetus) for a further 2 days.  142 
 143 
NIST refers here to a standard reference source of total UPM (SRM-1648a) from the 144 
National Institute of Standards and Technology. SRM-1648a was prepared from UPM 145 
previously collected in St Louis, Missouri, over a 1-year period and was re-suspended in 3% 146 
methanol to prevent the oxidation of aryl hydrocarbons. Particles ranged from 1.35 to 147 
30.1μm in diameter (mean 5.85μm) and comprised a combination of polycyclic aromatic 148 
hydrocarbons, polychlorinated biphenyl congeners, and chlorinated pesticides (23). 149 
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Surface staining 150 
DCs were harvested using 2mM EDTA in PBS containing 2% FCS then incubated on ice 151 
with different antibodies – CD40-FITC, ILT1-PE, ILT3-APC and CCR7-PE (BioLegend; 5C3, 152 
24, ZM4.1 and G043H7 respectively), CD83-APC, HLA-DR-PerCP, ILT2-PECy7 and ILT4- 153 
AlexaFluor647 (BD Biosciences; HB15e, L243, GHI/75 and 287219 respectively). DCs were 154 
washed and fluorescence assessed using an NxT Attune (ThermoFisher).  155 
 156 
Cell proliferation 157 
Prior to culture T cells were labeled with 5μM CellTrace Violet (ThermoFisher). Cell 158 
proliferation was assessed on day 7 of co-culture by loss of fluorescence intensity. 159 
 160 
Intracellular cytokine staining 161 
Cells were stimulated at 37⁰C with 50ng/ml PMA and 500ng/ml Ionomycin for 1 hour, adding 162 
2µM Monensin for a further 4 hours. Cells were surface stained with CD4-PerCP (BD 163 
Biosciences; SK3) and aqua zombie (Biolegend) +/- CD161-BV412 (BD Biosciences; DX12) 164 
and MDR1-PerCPeFluor710 (ebiosciences; UIC2) before fixing and permeabilising them (BD 165 
Biosciences Fix/Perm kit). Samples were then incubated with the following antibodies: IL-166 
17A-APC and IL-22-eFluor450 (eBiosciences; eBio64DEC17 and 22URTI respectively); 167 
IFNγ-FITC, GM-CSF-PE, IL-10-PE, IL-13-PE and Granzyme B-AlexaFluor700 (BD 168 
Biosciences; 4S.B3, BVD2-21C11, JES3-9D7, JES10-5A2 and GB-11 respectively); 169 
IL-17F-AlexaFluor488, TNFα-FITC (Biolegend; Poly5166 and MAb11 respectively). 170 
 171 
Cytometric bead array  172 
Cytometric bead array (CBA) was employed to measure the concentration of cytokines 173 
within supernatants in accordance with the manufacturer’s instructions (BD Biosciences).  174 
 175 
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qRT-PCR 176 
RNA was isolated from Qiazol lysed cells using an miRNeasy Mini Kit (Qiagen). mRNA was 177 
converted to cDNA by using RevertAid Reverse Transcriptase and complementary reagents. 178 
qRT-PCR was performed in triplicate on a ViiA7 using taq-man probes (ThermoFisher). 179 
 180 
Data analysis 181 
Flow cytometry data were analyzed using FlowJo (Treestar Inc. version 10). Cumulative data 182 
were analyzed using Graphpad Prism version 6.00 for Windows. After assessing for a 183 
Gaussian distribution, statistics were performed as outlined in figure legends.  184 
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Results 185 
1,25(OH)2D3 counteracts UPM-driven myeloid DC maturation 186 
CD1c+ DCs are the precursors of CD11b- and CD11b+ DCs that line the airways and lung 187 
parenchyma respectively (24). Since both air pollution and vitamin D deficiency are 188 
associated with the incidence and severity of respiratory diseases, the impact of these 189 
factors on CD1c+ DC maturation and the downstream memory T cell responses was 190 
investigated. CD1c+ DCs were cultured for 20 hours in the presence of the indicated 191 
concentration of 1,25(OH)2D3 and/or a reference source of UPM (NIST SRM-1648a referred 192 
to as ‘NIST’), added at a concentration (5 μg/ml) determined to consistently stimulate DC 193 
maturation both here (Supplementary Figure 1A) and previously (25)). 50 ng/ml rhGM-CSF 194 
was added to all DC cultures as a substitute for that released by UPM-stimulated human 195 
bronchial epithelial cells (26, 27); this has previously been shown to enhance the CD1c+ DC 196 
maturation induced by NIST (28).  197 
 198 
Figure 1A shows a magnified image of the DCs clumping around the NIST particle 199 
agglomerates after 20 hours in culture, in contrast to the resting cells cultured in the 200 
presence of 3% methanol vehicle control (VC). DC surface staining was performed and both 201 
representative histograms and cumulative data are shown (Figure 1B/C). The VC did not 202 
modulate expression of the surface markers assessed, but there was a 1,25(OH)2D3 dose-203 
dependent downregulation in expression of CD40, CD83 and HLA-DR. This occurred 204 
alongside an upregulation in expression of the inhibitory receptor immunoglobulin-like 205 
transcript-3 (ILT3), as previously independently reported (29), but not of the ILT1, ILT2 or 206 
ILT4 molecules (Supplementary Figure 2A).  207 
 208 
In contrast, NIST dose-dependently increased expression of the maturation marker CD83 at 209 
the mRNA and protein level (Supplementary Figure 1A), such that expression was 210 
significantly enhanced relative to both the VC and 1,25(OH)2D3 condition (p<0.01) (Figure 211 
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1C). There was also a trend towards increased expression of the lymph node-homing 212 
receptor CCR7 on the NIST-treated DCs (Supplementary Figure 2A). Expression of HLA-213 
DR, CD40 and ILT3 was not consistently modulated by NIST treatment. Addition of 214 
1,25(OH)2D3 to culture with NIST significantly reduced expression of CD83 (p<0.01) and 215 
CD40 (p<0.05) relative to the NIST-only condition, whilst expression of ILT3 remained 216 
significantly elevated (p<0.05) (Figure 1C). Similarly levels of IL-6 (p<0.01) and TNFα 217 
(p=0.17) were elevated in NIST-treated DC culture supernatants after 20 hours 218 
(Supplementary Figure 2B). In support of this, mRNA expression of il6 was dose-219 
dependently elevated in NIST-primed DCs (Supplementary Figure 1B). Treatment of CD1a+ 220 
DCs derived from nasal turbinates with NIST modestly increased expression of CD40 and 221 
CCR7 in a small sample size, as well as a trend towards elevated levels of IL-6 in cell culture 222 
supernatants (p=0.0531) (Supplementary Figure 2C-D). 1,25(OH)2D3 alone had no effect, 223 
but appeared to counteract the elevated expression of CD40 and CCR7 as well as the 224 
augmented levels of IL-6 when added in combination with NIST. 225 
 226 
UPM-primed DCs drive a ‘Th17.1’-like phenotype which is opposed by 1,25(OH)2D3 227 
Considering the growing body of literature highlighting the existence of Th17 subsets and T-228 
helper cell plasticity (8, 30), alongside studies showing a link between air pollution and IL-229 
17A (25, 31), we aimed to phenotype NIST-driven IL-17A+ cells in greater detail. As well as 230 
significantly increasing the frequency of cells expressing IL-17A and IFN, co-culture of 231 
memory CD4+ T cells with NIST-primed CD1c+ DCs enhanced the proportion of cells 232 
expressing IL-17F, IL-22, GM-CSF and granzyme B (Figure 2A/B). Notably, the frequency of 233 
memory CD4+ T cells co-expressing IL-17A with IFN, GM-CSF or granzyme B was 234 
significantly elevated in the NIST condition as compared to the VC when shown as a 235 
percentage of all memory CD4+ T cells (Figure 2C), or as a percentage of total memory 236 
CD4+IL-17A+ T cells (Figure 2D). There was however no difference in the frequency of IL-237 
17A+IL13+ cells or IL-17A+IL-10+ cells between the conditions and minimal IL-17A/IL-10 co-238 
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expression. Of note, levels of LPS were less than 1 pg per well and the NIST-driven 239 
enhancement of IL-17A was double that induced by treating DCs with 10 μg/ml LPS (data 240 
not shown).  241 
 242 
In contrast to NIST alone, addition of 1,25(OH)2D3 +/- NIST reduced the frequency of IL-243 
17A+ and IFN+ cells as well as the percentage of IL-17A+IFN+ cells (Figure 3A/B), a 244 
characteristic of pro-inflammatory ‘Th17.1’ cells. 1,25(OH)2D3 similarly overcame the NIST-245 
driven enhancement in expression of IL-17F, IL-22, GM-CSF and granzyme B 246 
(Supplementary Figure 3A). Whereas NIST-primed DCs significantly increased memory 247 
CD4+ T cell proliferation, as previously published (25), 1,25(OH)2D3 appeared able to 248 
counteract this (p=0.05). There was not however any difference in the viability of memory 249 
CD4+ T cells co-cultured with DCs that had been pre-treated with 1,25(OH)2D3 and/or NIST 250 
(data not shown). 251 
 252 
Analysis of secreted cytokines present in culture supernatants reflected that of the 253 
intracellular cytokine staining (Figure 3C), with levels of IL-17A, IL-17F, IL-12/23p40 and 254 
IFN consistently elevated in the NIST-treated condition and reduced by co-incubation of 255 
DCs with 1,25(OH)2D3. Levels of IL-13 and IL-10 were variable and not consistently 256 
modulated by either 1,25(OH)2D3 and/or NIST. Beyond cytokines, NIST-primed DCs also 257 
increased T cell surface expression of the lectin-like receptor CD161 which was opposed by 258 
1,25(OH)2D3, with a more modest effect on expression of MDR1 (Figure 3D), both markers 259 
that have been associated with Th17.1 cells in humans (8). The mRNA expression of 260 
relevant Th17-associated transcription factors was additionally screened after 48 hours of 261 
co-culture and the data are shown in Supplementary Figure 3B; there was a trend towards 262 
increased expression of stat3, tbx21, mdr1 and irf4 in the NIST condition, with 1,25(OH)2D3 263 
treatment opposing this effect (p<0.05 for stat3, mdr1 and irf4; p=0.073 for tbx21). 264 
 265 
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Dexamethasone enhances the capacity of vitamin D to dampen the NIST-driven IL-266 
17A+IFN+ T cell response 267 
Given previous evidence of complimentary interactions between corticosteroids and vitamin 268 
D (14), we additionally examined the combination in the present cultures. Pre-treating 269 
CD1c+ DCs with the synthetic corticosteroid dexamethasone was, like 1,25(OH)2D3, able to 270 
counteract the NIST-driven pro-inflammatory profile (Figure 4). Dexamethasone reduced 271 
expression of CD83 and CCR7 on CD1c+ DCs (Figure 4A). Addition of vitamin D to 272 
dexamethasone-treated DCs further suppressed CD83 expression even in the presence of 273 
NIST. Dexamethasone also further enhanced the 1,25(OH)2D3-mediated induction of ILT3, 274 
an effect that was opposed by NIST. Downstream, priming DCs with dexamethasone alone 275 
or in combination with 1,25(OH)2D3 counteracted the ability of NIST treatment to promote 276 
autologous memory CD4+ T cell proliferation and reduced levels of IL-17A, IFN and IL-277 
23p40 within the cell culture supernatants (Figure 4B/C). Notably the combination of vitamin 278 
D and dexamethasone suppressed the NIST-induced IL-17A+IFN+ memory CD4+ T cell 279 
response to the greatest extent. 280 
 281 
UPM upregulates a population of IL-17A+IFN𝛾+ cells in part via enhanced endogenous 282 
IL-23 283 
Since NIST pre-treatment of CD1c+ DC drove a phenotypically pro-inflammatory Th17.1-like 284 
profile with an increased frequency of IL-17A+IFN+ cells and levels of IL-12/23p40 were 285 
significantly upregulated in co-culture supernatants, a role for IL-23 as an intermediate was 286 
investigated. Significantly enhanced DC production of IL-23 was firstly confirmed at the 287 
mRNA levels over a NIST dose response (Figure 5A). Of note, il12 mRNA expression in 288 
DCs was undetectable by qRT-PCR (Supplementary Figure 1C). A neutralizing antibody 289 
specific for IL-23p19, thereby inhibiting IL-23 but not IL-12, or a relevant isotype control was 290 
then added throughout the culture period. As Figure 5B shows, NIST-primed DCs 291 
significantly increased expression of il17a and mdr1 mRNA after 48 hours of co-culture in 292 
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the isotype condition in agreement with protein data from Figure 3, but this was significantly 293 
reduced by addition of anti-IL-23 into culture, whilst expression of il-10 was unaffected. 294 
Similarly at the protein level, although anti-IL-23p19 had no effect upon NIST-driven cell 295 
division, it did significantly reduce the frequency specifically of IL-17A+IFN+ cells (p<0.001; 296 
Figure 5C/D), with a more modest effect upon the IL-17A (p=0.089) and IFN (p=0.092) 297 
single positive populations.   298 
 14 
Discussion 299 
The current study demonstrates that pre-treatment of human myeloid DCs with a common 300 
reference source of UPM (NIST) alters their maturation state resulting in the expansion of a 301 
population of memory CD4+ T cells possessing a pro-inflammatory Th17.1-like phenotype. 302 
These cells are characterised by the co-expression of IL-17A with IFN, GM-CSF and 303 
Granzyme B, and are predicted to drive exacerbations of respiratory diseases. Our data 304 
indicate a central role for NIST-induced IL-23 synthesis by myeloid DC in driving this pro-305 
inflammatory Th17 response. An additional novel feature of these data is the evidence that 306 
UPM significantly increased expression of GM-CSF and the serine protease granzyme B, 307 
specifically enriching the proportion of cells co-expressing these cytokines with IL-17A 308 
(Figure 2). Granzyme B can be released from the granules of cytotoxic T cells and is 309 
traditionally thought of as mediating apoptosis of target cells, but it can also stimulate pro-310 
inflammatory cytokine release and drive extracellular matrix remodelling (32). Co-expression 311 
of IL-17A and granzyme B by CD4+ T cells has, to date, been implicated predominantly in 312 
neuroinflammation (33), but elevated levels of granzyme B have been associated with 313 
various diseases including autoimmune conditions, type I diabetes and asthma. Collectively 314 
these data suggest that UPM, via actions on the antigen presenting cell compartment, 315 
promotes a Th17 population with a potentially pathogenic phenotype. 316 
 317 
In contrast to the effects of NIST, vitamin D reduced both CD1c+ DC priming and the 318 
subsequent pro-inflammatory memory T cell response when added alone and in combination 319 
with NIST, instead promoting a more tolerogenic phenotype (Figure 1). Whilst the individual 320 
effects of NIST (19) and 1,25(OH)2D3 (20) on DC maturation have previously been published, 321 
the capacity of 1,25(OH)2D3 to oppose certain pro-inflammatory properties of NIST when 322 
added in combination is novel and important given that these two environmental factors co-323 
exist. Furthermore, the synthetic corticosteroid dexamethasone was similarly capable of 324 
reducing the expression of NIST-driven maturation markers on CD1c+ DCs, both alone and 325 
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more prominently when added in combination with 1,25(OH)2D3 (Figure 4). Most 326 
significantly 1,25(OH)2D3 counteracted the induction of the maturation marker CD83 on 327 
CD1c+ DCs as well as the heightened frequency of IL-17A+IFNγ+ memory CD4+ T cells 328 
induced by NIST-primed CD1c+ DCs. 1,25(OH)2D3 also reduced expression of other 329 
inflammatory cytokines GM-CSF, granzyme B, IL-17F and IL-22 (Supplementary Figure 3). It 330 
is properties such as this that might help to explain evidence that, for example, vitamin D 331 
insufficient children in Puerto Rico living close to a major road, and therefore traffic-related 332 
air pollution, had an elevated risk of severe asthma exacerbations (34). Notably, in the 333 
European Study of Cohorts for Air Pollution Effects (ESCAPE), the relative effect of air 334 
pollution on health outcomes differed between cohorts, with Scandinavian groups often 335 
being more sensitive despite lower levels of ambient PM (35). This may be due to 336 
geographical differences in PM composition and/or intrinsic population variation which 337 
warrant further study; for example, reduced UVR exposure in Scandinavian countries would 338 
lower circulating levels of vitamin D, which we show here to counteract certain potentially 339 
pathogenic properties of PM.  340 
 341 
The fact that priming DCs with a source of UPM increased the frequency of IL-17A+ cells 342 
concurs with studies in mouse (31, 36) and man (25, 31, 37) that identify links between air 343 
pollution and IL-17A, albeit in distinct experimental settings. However in this study, we 344 
extend this observation to show that NIST-primed DCs also enhanced the frequency of cells 345 
expressing Th17-associated cytokines IL-17F and IL-22 as well as IFN, GM-CSF and 346 
granzyme B. Critically a large proportion of the NIST-driven IL-17A+ cells in this study co-347 
expressed IL-17F, IL-22, IFN, GM-CSF and granzyme B, but not immunoregulatory IL-10 348 
(Figure 2), a phenotype that is indicative of a putatively pathogenic Th17 cell (Th17.1) (3, 4, 349 
6, 7). Furthermore, NIST-primed DCs increased T cell expression of MDR1 and CD161 in 350 
co-culture (Figure 3D), both of which have been associated with a pro-inflammatory Th17 351 
phenotype in humans (8). Although in mice this subset of Th17 cells has been shown to 352 
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drive autoimmune conditions in a GM-CSF-dependent manner, their functional role and in 353 
vivo existence in humans is less clear. Th17/Th1 cells have nonetheless been identified in 354 
humans, predominantly in the periphery, inflamed joints and the gut (5, 8, 38), but functional 355 
analysis and detailed phenotyping of these cells has been understandably limited to date.  356 
 357 
Production of both IL-17A and IFN has however been shown to inversely correlate with lung 358 
function after corticosteroid therapy in steroid-refractory asthmatics (39), and GM-CSF was 359 
elevated even during the asymptomatic stage of asthma (40). Moreover, pro-inflammatory 360 
MDR1+ human Th17 cells are reportedly resistant to a range of corticosteroids (8), a 361 
characteristic of both severe asthma and COPD as well as various autoimmune conditions. 362 
Recently, a study performed using the murine house dust mite model of asthma found that 363 
both dexamethasone and anti-IL-17A were required to alleviate diesel exhaust particle 364 
(DEP)-induced corticosteroid-refractory asthma (41). We however observed that using the 365 
present in vitro co-culture system, priming of CD1c+ DCs from healthy donors in the 366 
presence of dexamethasone dampened the resultant NIST-driven proliferation and IL-367 
17A/IFN memory CD4+ T cell profile response, with no effect upon levels of IL-10 (Figure 368 
4). This conforms to data showing that dexamethasone-treated monocyte-derived DCs 369 
possessed a stable tolerogenic phenotype (42). Nonetheless acting directly on human T 370 
cells both we (9, 39) and others (43) observed that corticosteroids failed to inhibit IL-17A 371 
production and enhanced levels of IL-10 using various in vitro and ex vivo experimental 372 
systems, highlighting the importance of the context in which corticosteroids are 373 
administered.  374 
 375 
Considering the phenotype of the NIST-driven IL-17A+ cells and the fact that il23 mRNA 376 
expression was significantly upregulated in DCs alongside enhanced levels of IL-12/23p40 in 377 
culture supernatants, it was hypothesised that NIST acted via enhanced IL-23 activity to 378 
promote the pro-inflammatory Th17 response. Indeed, specific neutralisation of IL-23 379 
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impaired the NIST-driven IL-17A and IFN response whilst maintaining levels of IL-10 and 380 
not affecting cell proliferation, most significantly targeting IL-17A+IFN+ cells (Figure 5). 381 
Importantly, as was true for vitamin D, anti-IL-23p19 did not obliterate all of the IL-382 
17A+IFN+ cells which concurs with another study in which only a subset of CCR6+CXCR3+ 383 
Th17/Th1 cells were IL-23 responsive (44). We therefore identify a novel pathway wherein 384 
NIST drives enhanced IL-23 production by CD1c+ DCs which promotes a putatively 385 
pathogenic Th17 cell response in co-culture; the molecular mechanisms by which NIST acts 386 
on the DCs to induce IL-23 are not fully understood. Previous work has however shown that 387 
NIST-primed DCs promote an effector memory CD4+ T cell response in a manner that is 388 
dependent upon HLA-DR (25), but that the effects are not due to LPS contamination (data 389 
not shown). We speculate that NIST might modify self-antigens that stimulate the DCs 390 
and/or that exogenous antigens such as viruses, bacteria or allergens are adsorbed to the 391 
NIST to drive the observed effects; studies to address this important question is on-going.  392 
 393 
1,25(OH)2D3 significantly reduced the concentration of IL-12/23p40 when added in 394 
combination with NIST as well as the resultant Th17 response promoted by the NIST-pre-395 
treated DCs (Figure 3). However, addition of exogenous recombinant IL-23 was unable to 396 
overcome the effect (data not shown) suggesting that 1,25(OH)2D3 is also likely to act 397 
through other mechanisms to dampen Th17 responses, although there may well be 398 
redundancy in the system. Indeed in vivo, 1,25(OH)2D3 is thought to act through several 399 
immunoregulatory mechanisms to dampen Th17 responses (14): ILT3, which was shown 400 
here to be upregulated by 1,25(OH)2D3 (Supplementary Figure 3B), may play a role in 401 
dampening the pro-inflammatory response since it has been reported to reduce the 402 
synthesis of IL-17A and IFNγ in mice (45). In contrast interferon regulatory factor (IRF)-4, 403 
which contains vitamin D response elements (46), promotes Th17 cell differentiation in mice 404 
(47) and was downregulated by 1,25(OH)2D3 at the mRNA level, with NIST having the 405 
reciprocal effect (Supplementary Figure 3B).  406 
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 407 
From a therapeutic perspective, we believe that the reported capacity of vitamin D to 408 
dampen, but not obliterate, adaptive Th17 responses is critical. It seems highly plausible that 409 
such effects act alongside the well-documented capacity of vitamin D to act on structural and 410 
innate cells to promote antimicrobial pathways (14). Vitamin D has also been shown to 411 
counteract other potentially detrimental properties of UPM beyond the data presented here. 412 
For example, vitamin D can protect epithelial cells from oxidative stress (48), a major 413 
consequence of PM exposure that has been implicated in asthma, and oppose the induction 414 
of airway inflammation (49). Of particular relevance in the context of corticosteroid-refractory 415 
disease, vitamin D can overcome the oxidative stress-induced impairment in the nuclear 416 
translocation of ligand-bound receptors such as the glucocorticoid receptor (50).  417 
 418 
This research further elucidates the mechanisms that are likely to contribute to the 419 
epidemiological associations between vitamin D deficiency, air pollution and respiratory 420 
diseases. Priming of CD1c+ DCs with NIST increased IL-23 synthesis, driving a 421 
phenotypically pro-inflammatory and potentially pathogenic Th17 profile. Addition of active 422 
vitamin D, alone or in combination with corticosteroids, was however able to counteract 423 
some of the effects of NIST whilst maintaining levels of IL-10, supporting the notion that 424 
restoring vitamin D sufficiency may help to control inflammatory diseases and counteract 425 
certain negative effects of air pollution. This might be particularly true in subgroups of 426 
individuals, such as those regularly exposed to high levels of air pollution and vitamin D 427 
deficient individuals.  428 
 429 
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Figures legends 613 
Figure 1: 1,25(OH)2D3 counteracts UPM-induced CD1c+ DC activation. 614 
Peripheral CD1c+ DCs cultured with 50 ng/ml rhGM-CSF alone (-) or in the presence of 10-9-615 
10-7M 1,25(OH)2D3 (V-xM), 5 μg/ml NIST and/or a vehicle control (VC) for 20 hours. A, light 616 
microscope images taken at 25-times magnification. Cell surface staining was performed 617 
and the MFI determined; shown are representative histograms (B) and cumulative data (C; 618 
n=3/5). Data assessed by a repeated-measures one-way ANOVA with Holm-Sidak’s multiple 619 
comparisons test. * p ≤0.05, ** p ≤0.01.  620 
 621 
Figure 2: UPM drives a putatively pathogenic Th17 cytokine response. 622 
Peripheral CD1c+ DCs cultured with 50 ng/ml rhGM-CSF and either vehicle control (black) 623 
or 5 μg/ml NIST (white) for 20 hours. Autologous memory CD4+ T cells were co-cultured for 624 
a further 5 days followed by a 2 day expansion in the presence of 10 IU/ml IL-2. Cells were 625 
then stimulated for 5 hours with PMA and Ionomycin prior to assessing intracellular cytokine 626 
expression. A, representative plots from independent experiments. B-D, cumulative data for 627 
the total frequency of cytokine-expressing cells (B), the frequency of IL-17A co-expressing 628 
cells (C) and the percentage of IL-17A+ cells that co-expressed the indicated cytokine (D) 629 
(n=5-7 except for IL-17A and IFNγ (n=21 and 16 respectively)). Data assessed by paired-t-630 
test comparing the vehicle and NIST; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 631 
 632 
Figure 3: Pre-treating CD1c+ DCs with 1,25(OH)2D3 counteracted the UPM-driven 633 
Th1/Th17 profile. 634 
Peripheral CD1c+ DCs cultured with 50 ng/ml rhGM-CSF in the presence of 10-7M 635 
1,25(OH)2D3, 5 μg/ml NIST and/or a vehicle control (VC) for 20 hours. Autologous CellTrace 636 
Violet-labelled memory CD4+ T cells were then added for a further 5 days after which 637 
supernatants were harvested before expanding the cells with 10 U/ml IL-2 for a further 2 638 
days. Cells were stimulated for 5 hours with PMA and Ionomycin prior to assessing 639 
intracellular cytokine expression. Shown are representative dot plots (A) and cumulative 640 
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data (B) for the percentage of cells divided and the frequency of cells expressing IL-17A and 641 
IFNγ (n=7-9; data assessed by repeated-measured one-way ANOVA with Tukey’s multiple 642 
comparison test). C, CBA was employed to assess the concentration of cytokines in 643 
supernatants harvested on day 5 of co-culture (n=6; data assessed by a Friedman test with 644 
Dunn’s multiple comparison test). D, surface expression of CD161 and MDR1 assessed on 645 
day 7 of co-culture (representative histogram n=2). * p ≤0.05, ** p ≤0.01, *** p ≤0.001. 646 
 647 
Figure 4: Pre-treating CD1c+ DCs with 1,25(OH)2D3 and dexamethasone countered the 648 
UPM-driven pro-inflammatory profile.  649 
Peripheral CD1c+ DCs cultured with 50 ng/ml rhGM-CSF in the presence of 10-7M 650 
1,25(OH)2D3 (VitD; V), 10-7M dexamethasone (Dex; D) and/or 5 μg/ml NIST for 20 hours. A, 651 
cell surface staining was performed and the MFI determined (n=5). Autologous CellTrace 652 
Violet-labelled memory CD4+ T cells added for a further 5 days and then supernatants 653 
harvested for CBA (C; n=6). B, after expanding the cells with 10 U/ml IL-2 for 2 days, cells 654 
were stimulated for 5 hours with PMA and Ionomycin prior to assessing intracellular cytokine 655 
expression (n=5). Data assessed by 2-way ANOVA with Sidak’s multiple comparisons test. * 656 
p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. 657 
 658 
Figure 5: UPM acts via IL-23 to drive the synthesis of IL-17A+IFNγ+ memory CD4+ T 659 
cells. 660 
Peripheral CD1c+ DCs cultured with 50 ng/ml rhGM-CSF in the presence of 10-7M 661 
1,25(OH)2D3, 1.25-20 μg/ml NIST (5 μg/ml unless stated) and/or a vehicle control (VC) for 662 
20 hours. A, DC pellets were harvested and RNA isolated for qRT-PCR; il23 gene 663 
expression is shown normalised to 18s endogenous control (data assessed by Friedman’s 664 
test with Dunn’s multiple comparisons test). B-D, Autologous CellTrace Violet-labelled 665 
memory CD4+ T cells were added after 20 hours DC priming; an isotype control or 2 μg/ml 666 
anti-IL-23p19 was added throughout the culture. B, after 48 hours of co-culture cells were 667 
harvested, RNA isolated and then qRT-PCR performed to assess mRNA expression relative 668 
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to the isotype and VC condition (n=5; data assessed by a 2-way ANOVA with Sidak’s 669 
multiple comparisons test; * p<0.05 between VC and NIST; # p<0.05 between isotype and 670 
anti-IL-23). C/D, on day 5 of co-culture supernatants were harvested and the cells expanded 671 
with 10 U/ml IL-2 for a further 2 days before stimulating for 5 hours with PMA and Ionomycin 672 
prior to assessing intracellular cytokine expression. Shown are representative plots (C) and 673 
cumulative data (D; n=8; data assessed by a two-tailed paired t-test, *** p ≤ 0.001).  674 
 675 
Supplementary Figure 1: Dose-dependent effects of NIST on CD1c+ DC maturation. 676 
Peripheral CD1c+ DCs cultured with 50 ng/ml rhGM-CSF in the presence of a vehicle control 677 
(VC) or 1.25-20 μg/ml NIST for 20 hours. Surface staining was performed and DC pellets 678 
were harvested and RNA isolated for qRT-PCR; gene expression is shown normalised to 679 
18s endogenous control. mRNA (A) and surface expression (B) of the maturation marker 680 
CD83. C, mRNA expression of the indicated cytokines by NIST-primed CD1c+ DCs. Data 681 
assessed by a Friedman’s test with Dunn’s multiple comparisons test (n=3/5); * p ≤0.05, ** p 682 
≤0.01. 683 
 684 
Supplementary Figure 2: The impact of UPM and 1,25(OH)2D3 on the profile of 685 
peripheral and tissue-derived myeloid DCs. 686 
Peripheral CD1c+ DCs (A/B) or CD1a+ DCs isolated from nasal turbinate tissue (C/D) were 687 
cultured with 50 ng/ml rhGM-CSF in the presence of 10-7M 1,25(OH)2D3, 5 μg/ml NIST 688 
and/or a vehicle control (VC) for 20 hours. A, cell surface staining was performed and the 689 
MFI determined (n=4). B, the concentration of cytokines in the supernatant was determined 690 
by CBA (n=4). C, Cell surface flow cytometry staining was performed and shown are 691 
representative histograms (Ci) alongside cumulative data (Cii; n=3). D, the concentration of 692 
IL-6 in 20-hour culture supernatants as determined by CBA show as raw data and fold 693 
change relative to the vehicle control (n=3). Data assessed by a Friedman’s test with Dunn’s 694 
multiple comparisons test; * p ≤0.05, ** p ≤0.01. 695 
 696 
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Supplementary Figure 3: 1,25(OH)2D3-primed DCs oppose a UPM driven pro-697 
inflammatory response. 698 
Peripheral CD1c+ DCs cultured with 50 ng/ml rhGM-CSF in the presence of 10-7M 699 
1,25(OH)2D3 (V), 5 μg/ml NIST and/or a vehicle control (VC) for 20 hours. Autologous 700 
memory CD4+ T cells were then added. A, on day 5 of the co-culture cells were expanded 701 
with 10 U/ml IL-2 for a further 2 days and then stimulated for 5 hours with PMA and 702 
Ionomycin prior to assessing intracellular cytokine expression. Shown are representative 703 
contour plots (n=3). B, after 48 hours of co-culture cells were harvested, RNA isolated and 704 
then qRT-PCR performed to assess mRNA expression relative to 18s endogenous control. 705 
Data assessed by one-way ANOVA with Tukey’s multiple comparisons; * p ≤0.05, ** p ≤0.01. 706 
  707 
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Figures 708 
Figure 1: 709 
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Figure 2: 712 
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Figure 3: 715 
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Figure 4: 717 
718 
  719 
M
F
I
CD83 HLA-DR CCR7 ILT3
- VitD Dex V+D
0
1000
2000
3000
4000
****
** **
- VitD Dex V+D
0
5000
10000
15000
- VitD Dex V+D
0
200
400
600
****
- VitD Dex V+D
0
500
1000
1500
****
B(ii)
%
 M
e
m
o
ry
 
C
D
4
+
 T
 c
e
lls
C
p
g
/m
l
IFNγ
IL
-1
7
A
NIST
Vehicle
- Vitamin D Dex
CellTrace Violet
M
o
d
a
l
-
1,25(OH)
2
D3
Dexamethasone
B(i)
A
IL-17A+ IFNγ+ IL-17A+IFNγ+ % cells divided
IL-17A IFNγ IL-12/23p40 IL-10
- VitD Dex V+D
0
10
20
30
*
- VitD Dex V+D
0
2
4
6
***
*
- VitD Dex V+D
0
1
2
3
*
- VitD Dex V+D
0
10
20
30
40
50
***
- VitD Dex V+D
0
50
100
150
200
250
**
- VitD Dex V+D
0
5000
10000
15000
*
- VitD Dex V+D
0
20
40
60
- VitD Dex V+D
0
50
100
150
**
Vehicle 
Control
NIST
 35 
Figure 5: 720 
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Supplementary Figure 1: 723 
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Supplementary Figure 2: 726 
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Supplementary Figure 3: 729 
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